Skip to main content
Clinical Trials/NCT06184594
NCT06184594Enrolling By InvitationNot Applicable

Developing and Testing a Digital Toolkit to Improve Colorectal Cancer Screening Rates in Federally Qualified Health Centers

Icahn School of Medicine at Mount Sinai1 site in 1 country400 target enrollmentStarted: January 24, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Enrollment
400
Locations
1
Primary Endpoint
Colorectal Cancer (CRC) Screening completion

Study Overview

Brief Summary

The purpose of this research study is to evaluate the efficacy of a digital navigation tool, called the eNav to improve colorectal cancer screening uptake among patients treated at federally qualified health centers (FQHC)s. The digital navigation tool includes a website and text messaging support. The website includes information, motivational support, decisional support and cues to action (e.g., ability to request a CRC screening test). The eNav tool also includes text-messaging based navigation (e.g., reminders, instructions to complete the screening test).

Detailed Description

This is a multi-site randomized clinical trial to evaluate the efficacy of the eNav Toolkit. A total of 400 participants will be from four FQHC clinics within the Institute for Family Health FQHC network. Participants will be randomly assigned to one of two groups:

  1. eNav group (N=200) or
  2. usual care group (N=200)

Participants will consent and complete a baseline questionnaire (demographics, medical information) 1-4 weeks before their primary care appointment.

Those in the intervention group will receive a link to the eNav website. The digital navigation tool includes a website and text-messaging support. The website includes information, motivational support, decisional support and cues to action (e.g., ability to request a CRC screening test). The eNav tool also includes text-messaging based navigation (e.g., reminders, instructions to complete the screening test).

The control group will receive standard clinical care.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
45 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patient treated at the Institute for Family Health (IFH)
  • Patient 45 to 75 years old
  • English or Spanish speaking
  • Able to provide consent within the study time frame (within a month of the primary care appointment
  • Patients have access to a computer, tablet or mobile device to access the eNav Toolkit OR willing to use a clinic provided device, in person at either IFH OR Mount Sinai
  • Patient scheduled for a primary care appointment at IFH
  • Patients are due for colorectal cancer screening (as determined by the health maintenance alert in the medical chart)

Exclusion Criteria

  • Unable to provide informed consent

Arms & Interventions

eNav intervention

Experimental

Subjects assigned to this arm will receive a link to the eNav website.

Intervention: eNav (Other)

Usual Care Group

Placebo Comparator

Subjects assigned to this arm will not receive the link to the website and will receive standard clinical care.

Intervention: Standard of Care (Other)

Outcomes

Primary Outcomes

Colorectal Cancer (CRC) Screening completion

Time Frame: End of study, at 6 months

CRC, Yes/No Medical chart review will determine whether the CRC screening was complete. If a patient does not have a CRC screening result recorded in their medical record, the research team will call the patient to inquire whether they have completed the CRC screening.

Secondary Outcomes

  • Number of participants who complete screening tests with adequate quality(End of study, at 6 months)
  • Number of participants who complete the screening test with inadequate preparation(End of study, at 6 months)
  • Adherence to follow up recommendations(End of study, at 6 months)
  • The Colorectal Cancer Screening Beliefs Instrument Score(Approximately 3-4 weeks after primary care appointment)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Sarah Miller

Assistant Professor

Icahn School of Medicine at Mount Sinai

Study Sites (1)

Loading locations...

Similar Trials